Literature DB >> 23651331

Laboratory-based scoring system for prediction of hepatic inflammatory activity in patients with autoimmune hepatitis.

Krzysztof Gutkowski1, Marek Hartleb, Teresa Kacperek-Hartleb, Maciej Kajor, Włodzimierz Mazur, Włodzimierz Zych, Bożena Walewska-Zielecka, Andrzej Habior, Marek Sobolewski.   

Abstract

BACKGROUND & AIMS: In autoimmune hepatitis (AIH), inflammation is closely related to fibrosis. Although transaminase levels are commonly used to assess hepatic inflammation, they may not relate directly to the histology. We developed a noninvasive diagnostic score as an alternative to liver biopsy to help optimize treatment for AIH and monitor disease progress.
METHODS: Eighty-two participants with type 1 AIH who had undergone liver biopsy were included (44 in training and 38 in validation sets). Liver histology was assessed according to the histologic activity index (HAI; score 0-18) and Ishak's histologic fibrosis index (HFI; score 0-6). High inflammation was defined as HAI>4, and advanced fibrosis was defined as HFI>2. Routine laboratory test findings and stepwise linear regression were used to develop the best models predicting HAI and HFI. The best cut-off value to predict high inflammation and advanced fibrosis for these formulas was then calculated based on receiver-operating characteristic analysis.
RESULTS: The cut-off value for a model predicting high inflammation was ≥3.57 (AUROC = 0.93; 95% CI: 0.86-1.00), with 100% sensitivity and 85% specificity. High inflammation was confirmed with an 81% positive predictive value and excluded with a 100% negative predictive value. In the validation set, the sensitivity, specificity, positive predictive value and negative predictive values were 100, 56, 88 and 100% respectively. The diagnostic yield of the fibrosis score was unsatisfactory.
CONCLUSIONS: The noninvasive inflammatory score based on four routine laboratory parameters discriminated patients with and without significant hepatic inflammation and may facilitate follow-up of type 1 AIH patients.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  autoimmune hepatitis; hepatic inflammation; histologic activity index; histologic fibrosis index; liver fibrosis

Mesh:

Year:  2013        PMID: 23651331     DOI: 10.1111/liv.12198

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

1.  Serum Biomarkers for Autoimmune Hepatitis Type 1: the Case for CD48 and a Review of the Literature.

Authors:  Mingli Hu; Zhengrui You; You Li; Bingyuan Huang; Nana Cui; Rui Wang; Yiran Wei; Bo Li; Jubo Liang; Qiaoyan Liu; Yikang Li; Hanxiao Wang; Qiwei Qian; Jun Zhang; Ruiling Chen; Zhuwan Lyu; Yong Chen; Xiao Xiao; Min Lian; Ruqi Tang; Qi Miao; Qixia Wang; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2022-06-03       Impact factor: 8.667

2.  Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis.

Authors:  Jin Wang; Neera Malik; Meng Yin; Thomas C Smyrk; Albert J Czaja; Richard L Ehman; Sudhakar K Venkatesh
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

3.  Performance and Utility of Transient Elastography and Non-Invasive Markers of Liver Fiibrosis in Patients with Autoimmune Hepatitis: A Single Centre Experience.

Authors:  Olympia E Anastasiou; Matthias Büchter; Hideo A Baba; Johannes Korth; Ali Canbay; Guido Gerken; Alisan Kahraman
Journal:  Hepat Mon       Date:  2016-10-31       Impact factor: 0.660

4.  Relationship between serum adenosine deaminase levels and liver histology in autoimmune hepatitis.

Authors:  Murat Torgutalp; Cumali Efe; Hakan Babaoglu; Taylan Kav
Journal:  World J Gastroenterol       Date:  2017-06-07       Impact factor: 5.742

Review 5.  Ultrasound findings in autoimmune hepatitis.

Authors:  Yi Dong; Andrej Potthoff; Christoph Klinger; Ana Paula Barreiros; Dariusz Pietrawski; Christoph F Dietrich
Journal:  World J Gastroenterol       Date:  2018-04-21       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.